Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-α) era

被引：26

作者：

Nacci, Francesca ^{[1
,2
,3
]}

Matucci-Cerinic, Marco ^{[1
,2
,3
]}

机构：

[1] Med & Deno Ctr Univ Florence, Dept Rheumatol AVC, Florence, Italy

[2] Med & Deno Ctr Univ Florence, Dept Biomed, Florence, Italy

[3] Med & Deno Ctr Univ Florence, Div Rheumatol AOUC, Florence, Italy

来源：

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2011年 / 25卷 / 03期

关键词：

Anti-TNF-alpha; Tuberculosis; Infections; ACTIVE RHEUMATOID-ARTHRITIS; FACTOR MONOCLONAL-ANTIBODY; PATIENT-REPORTED OUTCOMES; PEGOL PLUS METHOTREXATE; HEPATITIS-B; LATENT TUBERCULOSIS; FACTOR ANTAGONISTS; DOUBLE-BLIND; MYCOBACTERIUM-TUBERCULOSIS; OPPORTUNISTIC INFECTIONS;

D O I：

10.1016/j.berh.2011.06.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We review the global experience of infections in patients treated with tumour necrosis factor (TNIF)-alpha inhibitors, which shows that the overall incidence of severe infections is at least doubled. In particular, this is true regarding tuberculosis. Screening and prophylactic measures have substantially reduced but not eliminated the risk. Recent improvements in immunologic testing for non-Bacillus Calmette Guerin (BCG)-related antigens allow more sensitive identification of latent tuberculosis and wider use of such methods holds promise as pre-treatment screening instruments. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：375 / 388

页数：14

共 118 条

[41] Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk -: A multicenter active-surveillance report [J].